At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 911 enrolled
Drug / intervention
NVX-Cov2373drug
Likely dose
NVX-Cov2373 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Observer-Blinded, Phase 3 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
In Brief
A Phase 3 clinical trial evaluating NVX-Cov2373 for COVID-19 and SARS-CoV-2 Infection. Completed, enrolled 911 participants across 30 sites.
Detailed Summary
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, SARS-CoV-2 Infection
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartJul 2022
First PostedJul 2022
Primary CompletionAug 2022
Study CompletionSep 2022
TodayJul 2026
First PostedJul 18, 2022
Enrollment StartJul 11, 2022
Primary CompletionAug 17, 2022
Study CompletionSep 1, 2022
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 4.0 years ago
Interventions
NVX-Cov2373drug
Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1